Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
Bought 281.3K · Sold 553.1K
Bought 281.3K · Sold 553.1K
Sold 2.27M
Granted 16.6K
Granted 189.3K · Bought 800.0K · Sold 508.6K
Granted 32.8K · Sold 17.9K
Granted 130.4K · Bought 60.0K · Sold 150.1K
Granted 84.2K
Granted 67.4K · Sold 27.1K
Sold 10.9K
Bought 28.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +1 co-filerDirector · 18 transactions | — | 7.51Mas of Mar 2021 | — | 281.3K | 553.1K |
| Gordon Carl LDirector · 18 transactions | — | 4.98Mas of Mar 2021 | — | 281.3K | 553.1K |
| Goeddel David V +2 co-filers10% owner · 4 transactions | — | 4.62Mas of Apr 2020 | — | — | — |
| Guthart Leo +3 co-filers10% owner · 5 transactions | — | 4.33Mas of Nov 2020 | — | — | 2.27M |
| Column Group LLC +4 co-filers10% owner · 7 transactions | — | 4.05Mas of Nov 2021 | 16.6K | — | — |
| Svennilson PeterDirector, 10% owner · 4 transactions | — | 3.58Mas of Apr 2020 | — | — | — |
| Chacko JacobPRESIDENT AND CEO, Director · 45 transactions | — | 581.7K | 189.3K | 800.0K | 508.6K |
| Heyman Richard A.Director · 20 transactions | — | 254.9K | 32.8K | — | 17.9K |
| Piscitelli DominicChief Financial Officer · 22 transactions | — | 120.1K | 130.4K | 60.0K | 150.1K |
| Kunkel Lori AnneDirector · 5 transactions | — | 84.2K | 84.2K | — | — |
| Multani Pratik SChief Medical Officer · 7 transactions | — | 68.1K | 67.4K | — | 27.1K |
| Scheller Richard HDirector · 13 transactions | — | 39.1Kas of May 2021 | — | — | 10.9K |
| You AngieDirector · 2 transactions | — | 28.0Kas of Jun 2025 | — | 28.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.64M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.